Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Clinical trials sponsored by Shenzhen Fosun Kairos Biotechnology Co., Ltd., explained in plain language.
A subsidiary of Fosun Pharma focused on innovative biologics and biosimilars.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Can engineered immune cells tackle a tough kidney disease?
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental therapy called FKC289 for people with a type of kidney disease called primary membranous nephropathy that has come back or not responded to standard treatment. FKC289 uses the patient's own immune cells, which are modified in the lab to recog…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Engineered immune cells take aim at a rare Protein-Folding disease
⭐️ CURE ⭐️ Not yet recruitingThis trial is testing an experimental treatment called FKC289 for people with primary AL amyloidosis that has relapsed or not responded to standard care. FKC289 uses a patient's own immune cells, engineered to recognize and attack the abnormal plasma cells that produce the harmfu…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC